High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia

Ryoko Mabuchi, Takeshi Hara, Takuro Matsumoto, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Masahito Shimizu, Hiroyasu Ito, Yasuko Yamamoto, Kuniaki Saito, Hisataka Moriwaki, Hisashi Tsurumi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 M. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77%) and ≥ 2.4 M (75%). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76%) than in those with high L-kynurenine levels (11%) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors.

Original languageEnglish
Pages (from-to)92-98
Number of pages7
JournalLeukemia and Lymphoma
Volume57
Issue number1
DOIs
Publication statusPublished - 02-01-2016
Externally publishedYes

Fingerprint

Kynurenine
Acute Myeloid Leukemia
Serum
Indoleamine-Pyrrole 2,3,-Dioxygenase
Leukocyte Count
Cytogenetics
Tryptophan
Multivariate Analysis
Survival Rate
High Pressure Liquid Chromatography

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mabuchi, R., Hara, T., Matsumoto, T., Shibata, Y., Nakamura, N., Nakamura, H., ... Tsurumi, H. (2016). High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. Leukemia and Lymphoma, 57(1), 92-98. https://doi.org/10.3109/10428194.2015.1041388
Mabuchi, Ryoko ; Hara, Takeshi ; Matsumoto, Takuro ; Shibata, Yuhei ; Nakamura, Nobuhiko ; Nakamura, Hiroshi ; Kitagawa, Junichi ; Kanemura, Nobuhiro ; Goto, Naoe ; Shimizu, Masahito ; Ito, Hiroyasu ; Yamamoto, Yasuko ; Saito, Kuniaki ; Moriwaki, Hisataka ; Tsurumi, Hisashi. / High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. In: Leukemia and Lymphoma. 2016 ; Vol. 57, No. 1. pp. 92-98.
@article{9c6b086f06324edc8feca12babb0744d,
title = "High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia",
abstract = "The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 M. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77{\%}) and ≥ 2.4 M (75{\%}). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76{\%}) than in those with high L-kynurenine levels (11{\%}) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors.",
author = "Ryoko Mabuchi and Takeshi Hara and Takuro Matsumoto and Yuhei Shibata and Nobuhiko Nakamura and Hiroshi Nakamura and Junichi Kitagawa and Nobuhiro Kanemura and Naoe Goto and Masahito Shimizu and Hiroyasu Ito and Yasuko Yamamoto and Kuniaki Saito and Hisataka Moriwaki and Hisashi Tsurumi",
year = "2016",
month = "1",
day = "2",
doi = "10.3109/10428194.2015.1041388",
language = "English",
volume = "57",
pages = "92--98",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

Mabuchi, R, Hara, T, Matsumoto, T, Shibata, Y, Nakamura, N, Nakamura, H, Kitagawa, J, Kanemura, N, Goto, N, Shimizu, M, Ito, H, Yamamoto, Y, Saito, K, Moriwaki, H & Tsurumi, H 2016, 'High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia', Leukemia and Lymphoma, vol. 57, no. 1, pp. 92-98. https://doi.org/10.3109/10428194.2015.1041388

High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. / Mabuchi, Ryoko; Hara, Takeshi; Matsumoto, Takuro; Shibata, Yuhei; Nakamura, Nobuhiko; Nakamura, Hiroshi; Kitagawa, Junichi; Kanemura, Nobuhiro; Goto, Naoe; Shimizu, Masahito; Ito, Hiroyasu; Yamamoto, Yasuko; Saito, Kuniaki; Moriwaki, Hisataka; Tsurumi, Hisashi.

In: Leukemia and Lymphoma, Vol. 57, No. 1, 02.01.2016, p. 92-98.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia

AU - Mabuchi, Ryoko

AU - Hara, Takeshi

AU - Matsumoto, Takuro

AU - Shibata, Yuhei

AU - Nakamura, Nobuhiko

AU - Nakamura, Hiroshi

AU - Kitagawa, Junichi

AU - Kanemura, Nobuhiro

AU - Goto, Naoe

AU - Shimizu, Masahito

AU - Ito, Hiroyasu

AU - Yamamoto, Yasuko

AU - Saito, Kuniaki

AU - Moriwaki, Hisataka

AU - Tsurumi, Hisashi

PY - 2016/1/2

Y1 - 2016/1/2

N2 - The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 M. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77%) and ≥ 2.4 M (75%). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76%) than in those with high L-kynurenine levels (11%) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors.

AB - The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 M. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77%) and ≥ 2.4 M (75%). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76%) than in those with high L-kynurenine levels (11%) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors.

UR - http://www.scopus.com/inward/record.url?scp=84954287348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954287348&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1041388

DO - 10.3109/10428194.2015.1041388

M3 - Article

VL - 57

SP - 92

EP - 98

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -